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Conclusions. Proteomic profiling of saliva has the potential to provide an effective tool for early diagnosis and prog-
nostication of OSCC.
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Background. Bisphosphonates-associated osteonecrosis of the jaws (BRONJ) is a serious complication, which has
been defined by Bedogni et al. (1) as an adverse drug reaction consisting of progressive destruction and death of
bone that affects the mandible and/or maxilla of patients exposed to the treatment with nitrogen-containing bisphos-
phonates (NBPs) in absence of a previous radiation treatment. Generally, IV NBPs have a strong association with
BRONJ than oral NBPs as evidenced by the higher incidence of BRONJ (0-10%) in patients treated with IV drugs
than in patients in oral therapy (<1%) (2).
Objectives. The aim of this study was to report a clinical case of BRONJ in an oncologic patient who has been treat-
ed with anastrozole and oral NBPs for secondary osteoporosis.
Case report. In February 2014 a 75-year-old woman was referred because of history of pain in the left posterior
mandibular region and hypoesthesia/anesthesia of the homolateral inferior lip and chin. In the anamnesis, she had
referred to be in therapy with alendronate since 2004, for a history of severe osteoporosis and, in multimodal
chemotherapy and anastrazole since 2010 for a diagnosis of breast cancer. Furthermore, left lower molar extraction
was performed on March 2013. Clinical examination revealed swelling of the extraoral soft tissue in the left emi-
mandible; intraorally, the presence of a mucosal fistula on the left mandibular angle was identified. CT was per-
formed and BRONJ diagnosis was defined with a stage 2A according to Bedogni et al. (1).
Conclusions. Administration of NBP is indicated to treat also osteoporosis anastrazole-induced in oncological pa-
tients, showing that patients with hormone receptor-positive early-stage breast cancer taking oral BP could represent
a subset in which it would be useful to apply BRONJ prevention protocols.
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Objectives. Trauma during dental surgery is the main predisposing factor for Medication Related Osteonecrosis of
the Jaws (MRONJ). Moreover, genetic factors are recognized in the pathogenesis. There are no specific guidelines
for the management of tooth extractions in patients under Bisphosphonates Therapy (BPT). 
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